Philips Q2: Regulatory Clearances for AI Imaging & SmartIQ Fuel 4% Growth

For biotech and pharma professionals, Philips' success in securing regulatory clearances for AI-powered innovations signals a growing role for advanced imaging in clinical trials and drug development. The 4% sales growth reflects market appetite for these tools, which could accelerate the move toward more precise patient selection and treatment monitoring.

Royal Philips delivered a solid second-quarter performance in 2026, posting 4% comparable sales growth across all business segments. The top-line expansion was accompanied by a notable jump in adjusted EBITA margin to 16.4%, though this was heavily influenced by a one-off benefit: a US tariff refund that contributed approximately 4.2 percentage points. Stripping out that refund, the underlying margin slightly contracted, pressured by persistent cost inflation and the direct impact of higher tariffs—headwinds that were only partially mitigated by volume gains and the company’s ongoing productivity program. The results highlight both Philips’ operational resilience and the significant, albeit temporary, financial lift provided by trade policy reversals.

“

Royal Philips delivered a solid second-quarter performance in 2026, posting 4% comparable sales growth across all business segments.

The 4% comparable sales growth was broad-based. Diagnosis & Treatment, which includes the company’s image-guided therapy and precision diagnosis businesses, grew 2% on a comparable basis, supported by healthy demand for its interventional systems. Connected Care also contributed positively, though its comparable order intake declined 1% overall, masking divergent trends: Europe saw strong double-digit order growth, reflecting robust provider investment in patient monitoring and hospital equipment, while North America experienced a timing-related dip as several large orders shifted into the third quarter. This geographic skew suggests that underlying demand in Philips’ largest market remains intact, and the third-quarter pipeline could see a rebound. The company’s order book dynamics, when combined with the reiterated full-year comparable sales growth outlook, suggest management confidence in sustained commercial momentum.

The most consequential financial event of the quarter was the largely completed US tariff refund process. This one-time cash inflow and margin uplift allowed Philips to raise its full-year guidance for adjusted EBITA and free cash flow, even as it maintained its comparable sales growth forecast. The tariff refund also boosted net cash flows from operating activities, offsetting higher working capital outflows and underscoring the importance of trade policy developments for a global manufacturer of medical equipment. Despite this windfall, the underlying profitability story reflects an ongoing grind: input cost inflation and tariff exposure are real, and the productivity program—while on track—is only just keeping pace. Investors should note that without the refund, adjusted EBITA would have dipped year-over-year, highlighting the fragility of margin progression in the current macro environment.